Activities of SYK and PLCγ2 Predict Apoptotic Response of CLL Cells to SRC Tyrosine Kinase Inhibitor Dasatinib
Zibo Song(Cornell University), Y. Lynn Wang(Southwest Medical University), Peter Martin(Northwestern University), Lauren Tyrell(Cornell University), Morton Coleman(Cornell University), Francis Y. Lee(Yale University), Pin Lu(University of Chicago), Richard R. Furman(Cornell University), Daniel M. Knowles(Cornell University), John P. Leonard(New York University)
Cited by 60
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k